Article info
PDFResearch ethics
Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society
- Correspondence to Miss Manik Chahal, Department of Oncology, University of Alberta, Cross Cancer Institute, 11560 University Avenue, Edmonton T6G1Z2 AB, Canada; manik{at}ualberta.ca
Citation
Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society
Publication history
- Received August 4, 2009
- Revised March 10, 2010
- Accepted March 12, 2010
- First published May 28, 2010.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines
- Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials
- Donor-funded research: permissible, not perfect
- Engaging African ancestry participants in SLE clinical trials
- Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
- Development of a home-visit nursing scale for helping spousal caregivers of terminal cancer patients develop positive perspectives of their caregiving experiences: a cross-sectional study
- Quackery or quality: the ethicolegal basis for a legislative framework for medical innovation
- Phase I oncology trials: why the therapeutic misconception will not go away
- Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer
- FDA proposes changes in access and charges for experimental drugs